Kyntra Bio
KYNB
182 hedge funds and large institutions have $2.58B invested in Kyntra Bio in 2017 Q3 according to their latest regulatory filings, with 44 funds opening new positions, 75 increasing their positions, 42 reducing their positions, and 11 closing their positions.
300% more first-time investments, than exits
New positions opened: 44 | Existing positions closed: 11
110% more capital invested
Capital invested by funds: $1.23B → $2.58B (+$1.35B)
79% more repeat investments, than reductions
Existing positions increased: 75 | Existing positions reduced: 42
67% more funds holding in top 10
Funds holding in top 10: 3 → 5 (+2)
21% more funds holding
Funds holding: 151 → 182 (+31)
0.25% more ownership
Funds ownership: 2.17% → 2.42% (+0.25%)
46% less call options, than puts
Call options by funds: $18.4M | Put options by funds: $33.9M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
+$139M |
| 2 |
BlackRock
New York
|
+$45.5M |
| 3 |
EAM
Eagle Asset Management
St Petersburg,
Florida
|
+$35M |
| 4 |
HIM
Hillhouse Investment Management
Grand Cayman,
Cayman Islands
|
+$31M |
| 5 |
VOYA Investment Management
Atlanta,
Georgia
|
+$24.2M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
OFM
Omega Fund Management
Boston,
Massachusetts
|
-$13.2M |
| 2 |
BIM
Bogle Investment Management
Newton Lower Falls,
Massachusetts
|
-$9.86M |
| 3 |
FCMI
Foresite Capital Management III
Larkspur,
California
|
-$8.07M |
| 4 |
American Century Companies
Kansas City,
Missouri
|
-$7.84M |
| 5 |
Prudential Financial
Newark,
New Jersey
|
-$6.01M |
KYNB Hedge Fund Activity: Q3 2017 in Review
182 of the 4,021 institutional investors tracked by Wall St. Rank reported a position in Kyntra Bio (KYNB) for Q3 2017, worth a combined $2.58B — up 110% from $1.23B a quarter earlier.
Buyers outnumbered sellers: 44 funds opened new KYNB positions and 11 closed out — a net gain of 33 holders — while 75 added to existing stakes and 42 trimmed.
The largest buyer was Fidelity Investments, adding an estimated $139M. The largest seller was Omega Fund Management, cutting an estimated $13.2M.
- 182 institutional investors held Kyntra Bio (KYNB) as of Q3 2017, up from 151 in Q2 2017.
- Funds reported $2.58B of Kyntra Bio stock for Q3 2017, up 110% quarter-over-quarter.
- 44 funds opened new Kyntra Bio positions in Q3 2017 and 11 closed out, a net change of +33 holders.
- The largest Kyntra Bio buyer in Q3 2017 was Fidelity Investments, an estimated $139M added.
- The largest Kyntra Bio seller in Q3 2017 was Omega Fund Management, an estimated $13.2M sold.
Based on aggregated 13F filings for Q3 2017.